2022
DOI: 10.3390/v14071381
|View full text |Cite
|
Sign up to set email alerts
|

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses

Abstract: The emergence of significant arboviruses and their spillover transmission to humans represent a major threat to global public health. No approved drugs are available for the treatment of significant arboviruses in circulation today. The repurposing of clinically approved drugs is one of the most rapid and promising strategies in the identification of effective treatments for diseases caused by arboviruses. Here, we screened small-molecule compounds with anti-tick-borne encephalitis virus, West Nile virus, yell… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 45 publications
0
4
0
Order By: Relevance
“…TBEV was stocked in the laboratory as described previously ( Ding et al, 2022 ; Tang et al, 2022 ). TBEV was propagated in Vero cells, and cell culture supernatants collected at 72 h post-inoculation were centrifuged at 2,500 rpm for 10 min to remove cell debris.…”
Section: Methodsmentioning
confidence: 99%
“…TBEV was stocked in the laboratory as described previously ( Ding et al, 2022 ; Tang et al, 2022 ). TBEV was propagated in Vero cells, and cell culture supernatants collected at 72 h post-inoculation were centrifuged at 2,500 rpm for 10 min to remove cell debris.…”
Section: Methodsmentioning
confidence: 99%
“…TBEV was stocked in the laboratory as described previously (Ding et al, 2022;Tang et al, 2022). TBEV was propagated in Vero cells, and cell culture supernatants collected at 72 h post-inoculation were centrifuged at 2,500 rpm for 10 min to remove cell debris.…”
Section: Virus Propagationmentioning
confidence: 99%
“…Currently, besides bortezomib, two other proteasome inhibitors are in clinical use (carfilzomib and ixazomib). In contrast, indirect approaches to limit ERAD have failed clinical trials due to off-target effects or poor specificity (Marciniak et al 2022 ; Zhai et al 2021 ; Ding et al 2022 ; Alrasheed et al 2021 ).…”
Section: Cancer Cells Benefit From the Uprmentioning
confidence: 99%